The stock of Kazia Therapeutics Limited ADR (NASDAQ: KZIA) has increased by 16.43% when compared to last closing price of $6.82. Despite this, the company has experienced a 19.86% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-07-09 that SYDNEY, July 9, 2025 /PRNewswire/ — Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy after completing Cycle 1 (21 days) of dosing. The patient, a 61-year-old woman with metastatic triple-negative breast cancer localized to the left upper lobe of the lung, has shown highly encouraging preliminary results at 21 days, with a >50% reduction in circulating tumor cells (CTCs) and a notable decrease in CTC clusters.
Is It Worth Investing in Kazia Therapeutics Limited ADR (NASDAQ: KZIA) Right Now?
KZIA has 36-month beta value of 2.62. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The average trading volume of KZIA on July 09, 2025 was 895.52K shares.
KZIA’s Market Performance
The stock of Kazia Therapeutics Limited ADR (KZIA) has seen a 19.86% increase in the past week, with a 40.65% rise in the past month, and a 123.85% gain in the past quarter. The volatility ratio for the week is 12.37%, and the volatility levels for the past 30 days are at 14.72% for KZIA. The simple moving average for the past 20 days is 5.80% for KZIA’s stock, with a -31.08% simple moving average for the past 200 days.
Analysts’ Opinion of KZIA
Many brokerage firms have already submitted their reports for KZIA stocks, with Maxim Group repeating the rating for KZIA by listing it as a “Buy.” The predicted price for KZIA in the upcoming period, according to Maxim Group is $3 based on the research report published on February 06, 2025 of the current year 2025.
Maxim Group, on the other hand, stated in their research note that they expect to see KZIA reach a price target of $18. The rating they have provided for KZIA stocks is “Buy” according to the report published on October 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to KZIA, setting the target price at $17 in the report published on January 05th of the previous year.
KZIA Trading at 49.39% from the 50-Day Moving Average
After a stumble in the market that brought KZIA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.94% of loss for the given period.
Stock Fundamentals for KZIA
Current profitability levels for the company are sitting at:
- 1.0 for the gross margin
The net margin for Kazia Therapeutics Limited ADR stands at -11.6. Equity return is now at value -3028.18, with -135.08 for asset returns.
Based on Kazia Therapeutics Limited ADR (KZIA), the company’s capital structure generated -0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -15.11.
Currently, EBITDA for the company is -26.77 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 4.95. The receivables turnover for the company is 17.35for trailing twelve months and the total asset turnover is 0.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.21.
Conclusion
To put it simply, Kazia Therapeutics Limited ADR (KZIA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
